制备了一系列酰胺基丙烯基异羟肟酸衍生物,作为人类组蛋白脱乙酰基酶(HDAC)的新型抑制剂。在HDAC抑制试验中,几种化合物在<100 n M时表现出效价,亚微摩尔IC 50在针对三种肿瘤细胞系的测试中获得了最佳值,并观察到了人类和小鼠微粒体的显着稳定性。选择了三种代表性化合物进行进一步表征,并针对一系列I类和II类HDAC进行了选择性分析,并进行了初步的体内药代动力学(PK)实验。尽管它们具有很高的微粒体稳定性,但它们在体内PK研究以及大鼠和人类肝细胞中均显示出中到高的清除率,这表明非微粒体酶催化了主要的代谢途径。
Measurements of fluorescence spectra of a series of polymethylene bis(p-(2-ethoxycarbonylvinyl)cinnamates) [(CH2)n(p-PDAmC2)2 (n=2–12)] in various solvents indicate that alcoholic solvents induce intramolecular association of the diacrylate chromophores, exhibiting excited pair emission, of which the intensity is dependent upon the methylene chain length.
This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1 C6 haloalkoxy; R2, R3 are, independently, hydrogen; C1-C6 alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH2)mCR4R5(CH2)n, or (CH2)oNR6(CH2)p; m, n, o, p, R4, R5 and R6 are as further defined in the specification; and pharmaceutical acceptable salts thereof.
This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R
1
is hydrogen, halogen, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, C
1
-C
6
haloalkyl or C
1
C
6
haloalkoxy; R
2
, R
3
are, independently, hydrogen; C
1
-C
6
alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH
2
)
m
CR
4
R
5
(CH
2
)
n
, or (CH
2
)
o
NR
6
(CH
2
)
p
; m, n, o, p, R
4
, R
5
and R
6
are as further defined in the specification; and pharmaceutical acceptable salts thereof.
[EN] HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES COMME INHIBITEURS DES HDAC
申请人:DAC SRL
公开号:WO2009150129A1
公开(公告)日:2009-12-17
This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy; R2, R3 are, independently, hydrogen; C1-C6 alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH2)mCR4R5(CH2)n, or (CH2)oNR6(CH2)p; m, n, o, p, R4, R5 and R6 are as further defined in the specification; and pharmaceutical acceptable salts thereof.
Loew, Justus Liebigs Annalen der Chemie, 1885, vol. 231, p. 363